These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A consideration of the patentability of enantiomers in the pharmaceutical industry in the United States. Miller CP; Ullrich JW Chirality; 2008 Jun; 20(6):762-70. PubMed ID: 18200591 [TBL] [Abstract][Full Text] [Related]
3. U.S. v. Barr Laboratories: a technical perspective. Madsen RE PDA J Pharm Sci Technol; 1994; 48(4):176-9. PubMed ID: 7804814 [No Abstract] [Full Text] [Related]
5. Chirality and its importance in drug development. Campbell DB; Wilson K Biochem Soc Trans; 1991 Apr; 19(2):472-5. PubMed ID: 1889635 [No Abstract] [Full Text] [Related]
6. An EU perspective on the use of in vitro methods in regulatory pharmaceutical toxicology. Snodin DJ Toxicol Lett; 2002 Feb; 127(1-3):161-8. PubMed ID: 12052654 [TBL] [Abstract][Full Text] [Related]
7. Regulatory implications: a committee member's perspective. Brown JR Biochem Soc Trans; 1991 Apr; 19(2):463-5. PubMed ID: 1889631 [No Abstract] [Full Text] [Related]
8. Regulatory and quality considerations for continuous manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium. Allison G; Cain YT; Cooney C; Garcia T; Bizjak TG; Holte O; Jagota N; Komas B; Korakianiti E; Kourti D; Madurawe R; Morefield E; Montgomery F; Nasr M; Randolph W; Robert JL; Rudd D; Zezza D J Pharm Sci; 2015 Mar; 104(3):803-12. PubMed ID: 25830179 [TBL] [Abstract][Full Text] [Related]
9. High-throughput and parallel screening methods in asymmetric hydrogenation. Jäkel C; Paciello R Chem Rev; 2006 Jul; 106(7):2912-42. PubMed ID: 16836304 [No Abstract] [Full Text] [Related]
13. Evaluation of similar biotherapeutic products: scientific and regulatory challenges. Griffiths E; Thorpe R; Wadhwa M; Sohn Y Biologicals; 2011 Sep; 39(5):249. PubMed ID: 21925898 [No Abstract] [Full Text] [Related]
14. Secondary wholesalers oppose FDA pedigree regulation. Young D Am J Health Syst Pharm; 2001 Sep; 58(18):1698, 1700. PubMed ID: 11571811 [No Abstract] [Full Text] [Related]
15. The science and politics of medicines control. Abraham J Drug Saf; 2003; 26(3):135-43. PubMed ID: 12580644 [TBL] [Abstract][Full Text] [Related]
16. Analysis of pharmaceutical product diversion and the gray market: cheaper drugs, but at what cost? Dooley K; Sullivan JA Health Care Law Mon; 2010 Oct; 2010(10):2-8. PubMed ID: 21302589 [No Abstract] [Full Text] [Related]
17. Combating counterfeit drugs. Land T Nature; 1992 Jan; 355(6357):192. PubMed ID: 1731208 [No Abstract] [Full Text] [Related]
18. Continuous Manufacturing in Pharmaceutical Process Development and Manufacturing. Burcham CL; Florence AJ; Johnson MD Annu Rev Chem Biomol Eng; 2018 Jun; 9():253-281. PubMed ID: 29879381 [TBL] [Abstract][Full Text] [Related]
19. Report suggests steps to improve safety of drug supply. Traynor K Am J Health Syst Pharm; 2011 Sep; 68(17):1570, 1574. PubMed ID: 21856799 [No Abstract] [Full Text] [Related]
20. The "spurious drugs" gene and its pervasiveness. Srinivasan S Indian J Med Ethics; 2010; 7(3):136-9. PubMed ID: 20806518 [No Abstract] [Full Text] [Related] [Next] [New Search]